These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 19809220)

  • 1. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
    Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
    J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
    Hiuge-Shimizu A; Maeda N; Hirata A; Nakatsuji H; Nakamura K; Okuno A; Kihara S; Funahashi T; Shimomura I
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological profile of a novel, non-TZD PPARgamma agonist.
    Chen X; Osborne MC; Rybczynski PJ; Zeck R; Yang M; Xu J; Zhou L; Cryan E; Tang Y; Demarest KT
    Diabetes Obes Metab; 2005 Sep; 7(5):536-46. PubMed ID: 16050946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
    Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
    Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
    Konda VR; Desai A; Darland G; Grayson N; Bland JS
    PLoS One; 2014; 9(1):e87848. PubMed ID: 24498211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
    Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
    Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
    Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
    J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of KY-903, a Novel Tetrazole-Based Peroxisome Proliferator-Activated Receptor γ Modulator, in Male Diabetic Mice and Female Ovariectomized Rats.
    Ito Y; Yamamoto M; Furukawa S; Fukui M; Morishita K; Kitao T; Shirahase H
    Biol Pharm Bull; 2021; 44(5):659-668. PubMed ID: 33952822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
    Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
    Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats.
    Pelzer T; Jazbutyte V; Arias-Loza PA; Segerer S; Lichtenwald M; Law MP; Schäfers M; Ertl G; Neyses L
    Biochem Biophys Res Commun; 2005 Apr; 329(2):726-32. PubMed ID: 15737646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
    Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
    Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
    Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
    Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice.
    Zhang B; Graziano MP; Doebber TW; Leibowitz MD; White-Carrington S; Szalkowski DM; Hey PJ; Wu M; Cullinan CA; Bailey P; Lollmann B; Frederich R; Flier JS; Strader CD; Smith RG
    J Biol Chem; 1996 Apr; 271(16):9455-9. PubMed ID: 8621615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.
    Goto T; Nakayama R; Yamanaka M; Takata M; Takazawa T; Watanabe K; Maruta K; Nagata R; Nagamine J; Tsuchida A; Kato H
    Exp Clin Endocrinol Diabetes; 2015 Sep; 123(8):492-9. PubMed ID: 26011171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes.
    Chakrabarti R; Vikramadithyan RK; Kumar MP; Kumar SK; Mamidi NV; Misra P; Suresh J; Hiriyan J; Rao CS; Rajagopalan R
    Diabetes Obes Metab; 2002 Sep; 4(5):319-28. PubMed ID: 12190995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
    Brown KK; Henke BR; Blanchard SG; Cobb JE; Mook R; Kaldor I; Kliewer SA; Lehmann JM; Lenhard JM; Harrington WW; Novak PJ; Faison W; Binz JG; Hashim MA; Oliver WO; Brown HR; Parks DJ; Plunket KD; Tong WQ; Menius JA; Adkison K; Noble SA; Willson TM
    Diabetes; 1999 Jul; 48(7):1415-24. PubMed ID: 10389847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes.
    Kong AP; Yamasaki A; Ozaki R; Saito H; Asami T; Ohwada S; Ko GT; Wong CK; Leung GT; Lee KF; Yeung CY; Chan JC
    Diabetes Obes Metab; 2011 Sep; 13(9):806-13. PubMed ID: 21492364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.